Billy Branch, MD
Internal Medicine · Sterlington, LANPI 1780975565
Payments from drug & device makers
Across 228 payments — averaging $16.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$633
- AbbVie$572
- Bayer$357
- Lilly USA, LLC$287
- Boehringer Ingelheim$264
- Amgen$257
- plus $1K from 28 others
What the payments were for
- Food & beverage$3,808100%
- Education$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 42 | $633 |
| AbbVie(2 entities) | 45 | $572 |
| Bayer | 24 | $357 |
| Lilly USA, LLC | 17 | $287 |
| Boehringer Ingelheim | 17 | $264 |
| Amgen(2 entities) | 11 | $257 |
| Pfizer | 7 | $241 |
| AstraZeneca | 5 | $186 |
| Esperion Therapeutics, Inc. | 11 | $158 |
| Teva Pharmaceuticals USA, Inc. | 9 | $120 |
| Sanofi-aventis U.S. LLC | 2 | $95 |
| Abbott | 4 | $60 |
| Arbor Pharmaceuticals, Inc. | 3 | $50 |
| Otsuka America Pharmaceutical, Inc. | 2 | $47 |
| Astellas Pharma US Inc | 3 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $41 |
| Exact Sciences | 2 | $34 |
| Boston Scientific | 2 | $32 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $28 |
| GSK | 1 | $28 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| Phathom Pharmaceuticals, Inc. | 1 | $27 |
| Philips North America LLC | 2 | $25 |
| Neurelis, Inc. | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Supernus Pharmaceuticals, Inc. | 1 | $22 |
| Eisai Inc. | 1 | $21 |
| Sobi, Inc | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Adlon Therapeutics L.p. | 1 | $17 |
| Avion Pharmaceuticals | 1 | $14 |
| Biogen | 1 | $14 |
| Genentech USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,827 in reported general payments places this provider in the 80th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 181 | $125,379 |
| MounjaroTirzepatide | 115 | $120,747 |
| OzempicSemaglutide | 114 | $105,631 |
| JardianceEmpagliflozin | 71 | $56,798 |
| JanuviaSitagliptin Phosphate | 60 | $55,532 |
| FarxigaDapagliflozin Propanediol | 58 | $47,078 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $45,586 |
| RybelsusSemaglutide | 39 | $43,394 |
| TrulicityDulaglutide | 28 | $33,583 |
| XareltoRivaroxaban | 38 | $26,063 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 53 | $22,764 |
| EntrestoSacubitril/Valsartan | 23 | $16,363 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $15,435 |
| MyrbetriqMirabegron | 18 | $13,228 |
| Xtampza ErOxycodone Myristate | 12 | $11,325 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $287 | $154,330143 claims |
| Novo NordiskOzempic, Rybelsus | $633 | $149,026153 claims |
| PfizerEliquis | $241 | $125,379181 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $186 | $57,74073 claims |
| Boehringer IngelheimJardiance | $264 | $56,79871 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $28 | $53,62971 claims |
| Astellas Pharma US IncMyrbetriq | $42 | $13,22818 claims |
| AbbVieLinzess | $572 | $10,92915 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $41 | $10,58322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Sterlington
- William SmithNew Orleans$50.5M
- Robert JeanfreauMetairie$13.4M
- Katherine PearceBaton Rouge$12M
- Ernest ThompsonBaker$2.1M
- Brian LewisNew Orleans$2M
- Otis BarnumNatchitoches$1.8M
- Satinder SainiCrowley$1.8M
- Randall MillerEunice$1.2M
- Donna RyanBaton Rouge$991K
- Steven DeitelzweigNew Orleans$939K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.